Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Study of dual nanobody VHHs-based CAR T targeting BCMA shows ORR of 96.3% (26/27 (including many with high risk features)), median duration of remission of 11 months (2-36 months); 1-year OS rate of 61.1%, and PFS of 57.2%.”
Title: Efficacy and Safety of BCMA Nanobody CAR-T Cell Therapy in Relapsed or Refractory Plasma Cell Myeloma
Authors: Xian Zhang, Lin Wang, Junfang Yang, Xiaona Hu, Hui Wang, Lina Zhang, Xiaoge Zhou, Ying Liu, Qinglong Wang, Peihua Lu
You can read the Full Article in Blood Advances.
More posts featuring Robert Orlowski.
